A phase 2 randomized, controlled, open-label (dose-blinded), multi-center, dose-finding study of the safety and efficacy of I-0401 in the treatment of patients with fractures of the tibial plateau requiring grafting. - N/A

Kuros Biosurgery AG0 个研究点目标入组 180 人开始时间: 2007年4月26日最近更新: 2022年8月8日

适应症

试验速览

暂无简介。

•1. Radiological evidence of fracture of the tibial plateau requiring grafting and fixation that occurs either alone or is part of a polytraumatic event (AO classification: 41B2, 41B3, 41C2, 41C3).
•2. Female and male subjects = 18 years.
•3. Body mass index (BMI) 16-33 (minimum body weight 50 kg, maximum 140 kg).
•4. Glasgow coma score (GCS) = 13.
•5. Females of child-bearing potential must be willing to undergo a pregnancy test (urine) prior to treatment start (at screening).
•6. Females of child-bearing potential randomized in the intervention group must agree to have acceptable contraception for at least 3 months after receiving I 0401.
•7. Subjects must be able and willing to come to the clinic for follow up visits as scheduled in the time and events schedule.
•8. Signed Informed Consent Form (ICF).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1. Total size of defect requiring a graft volume of > 7.0 mL.
•2. Patients with high risk of amputation.
•3. Open tibial plateau fractures Gustilo-Anderson grade III.
•4. Concomitant ipsilateral fractures of the limb other than the fracture of the tibial plateau.
•5. Active or past history of malignant tumor.
•6. Evidence of systemic or localized infection at time of surgery.
•7. Pregnant or lactating females.
•8. Evidence of immune-suppression.
•9. On treatment and/or planned treatment with products containing PTH (e.g. Forteo®, Forsteo®).
•10. Evidence of hypercalcemia.
•11. Known history of allergy to anesthetics.
•12. Suspected or known allergies towards any of the components of I-0401 (TGplPTH1-34, Fibrin, HA/TCP granules).
•13. History or evidence for any hereditary or acquired chronic bone disease.
•14. Known clinically significant organ or systemic diseases or any other relevant medical condition such that in the opinion of the investigator, the significance of the disease or condition will impose hazard to the patient if study therapy will be initiated or will compromise the subject’s participation in the study.
•15. Participation in another clinical trial within 3 months prior to trial start.

发起方